

1 **Identification of *de novo* mutations in prenatal neurodevelopment-associated genes in**  
2 **schizophrenia in two Han Chinese patient-sibling family-based cohorts**

3 **Running head: Identification of *de novo* mutations in schizophrenia in Chinese families**

4 Shan Jiang<sup>1,\*</sup>, Daizhan Zhou<sup>2,3,\*</sup>, Yin-Ying Wang<sup>1</sup>, Peilin Jia<sup>1</sup>, Chunling Wan<sup>2,3</sup>, Xingwang Li<sup>2,3</sup>,  
5 Guang He<sup>2,3</sup>, Dongmei Cao<sup>2</sup>, Xiaoqian Jiang<sup>4</sup>, Kenneth S. Kendler<sup>5</sup>, Ming Tsuang<sup>6</sup>, Travis  
6 Mize<sup>7,8</sup>, Jain-Shing Wu<sup>9</sup>, Yimei Lu<sup>9</sup>, Lin He<sup>2,3,10,#</sup>, Jingchun Chen<sup>9,#</sup>, Zhongming Zhao<sup>1,11,12,#</sup> and  
7 Xiangning Chen<sup>13,#</sup>

8 <sup>1</sup>Center for Precision Health, School of Biomedical Informatics, The University of Texas Health  
9 Science Center at Houston, Houston, TX 77030, USA.

10 <sup>2</sup>Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric  
11 Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science, Shanghai  
12 Jiao Tong University, Shanghai, China.

13 <sup>3</sup>Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai  
14 Jiao Tong University School of Medicine, Shanghai, China.

15 <sup>4</sup>School of Biomedical Informatics, The University of Texas Health Science Center at Houston,  
16 Houston, TX 77030, USA.

17 <sup>5</sup>Virginia Institute of Psychiatric and Behavioral Genetics, Medical College of Virginia and  
18 Virginia Commonwealth University, Richmond, VA, 23298, USA.

19 <sup>6</sup>Department of Psychiatry, University of California at San Diego, San Diego, CA, 92093, USA.

20 <sup>7</sup>Department of Ecology and Evolutionary Biology, University of Colorado Boulder, Boulder,  
21 CO 80309, USA.

22 <sup>8</sup>Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO 80309, USA.

23 <sup>9</sup>Nevada Institute of Personalized Medicine, University of Nevada Las Vegas, Las Vegas, NV  
24 89154, USA.

25 <sup>10</sup>Institute of Neuropsychiatric Science and Systems Biological Medicine, Shanghai Jiao Tong  
26 University, Shanghai, China.

27 <sup>11</sup>MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston,  
28 TX 77030, USA.

29 <sup>12</sup>Human Genetics Center, School of Public Health, The University of Texas Health Science  
30 Center at Houston, Houston, TX 77030, USA.

31 <sup>13</sup>410 AI, LLC, Germantown, MD 20876, USA.

32

33 \*These authors contributed equally.

34 #Correspondence: Lin He ([helin@bio-x.cn](mailto:helin@bio-x.cn)) or Jingchun Chen ([Jingchun.chen@unlv.edu](mailto:Jingchun.chen@unlv.edu)) or  
35 Zhongming Zhao ([Zhongming.Zhao@uth.tmc.edu](mailto:Zhongming.Zhao@uth.tmc.edu)) or Xiangning Chen  
36 ([va.samchen@gmail.com](mailto:va.samchen@gmail.com)).

37 **Abstract**

38 Schizophrenia (SCZ) is a severe psychiatric disorder with a strong genetic component. High  
39 heritability of SCZ suggests a major role for transmitted genetic variants. Furthermore, SCZ is  
40 also associated with a marked reduction in fecundity, leading to the hypothesis that alleles with  
41 large effects on risk might often occur *de novo*. In this study, we conducted whole-genome  
42 sequencing for 23 families from two cohorts with matched unaffected siblings and parents. Two  
43 nonsense *de novo* mutations (DNMs) in *GJCI* and *HIST1H2AD* were identified in SCZ patients.  
44 Ten genes (*DPYSL2*, *NBPF1*, *SDK1*, *ZNF595*, *ZNF718*, *GCNT2*, *SNX9*, *AACS*, *KCNQ1* and  
45 *MSI2*) were found to carry more DNMs in SCZ patients than their unaffected siblings by burden  
46 test. Expression analyses indicated that these DNM implicated genes showed significantly higher  
47 expression in prefrontal cortex in prenatal stage. The DNM in the *GJCI* gene is highly likely a  
48 loss function mutation (pLI = 0.94), leading to the dysregulation of ion channel in the  
49 glutamatergic excitatory neurons. Analysis of rare variants in independent exome sequencing  
50 dataset indicates that *GJCI* has significantly more rare variants in SCZ patients than in  
51 unaffected controls. Data from genome-wide association studies suggested that common variants  
52 in the *GJCI* gene may be associated with SCZ and SCZ-related traits. Genes co-expressed with  
53 *GJCI* are involved in SCZ, SCZ-associated pathways and drug targets. These evidence suggest  
54 that *GJCI* may be a risk gene for SCZ and its function may be involved in prenatal and early  
55 neurodevelopment, a vulnerable period for developmental disorders such as SCZ.

56 **Key words:** schizophrenia, *de novo* mutation, whole genome sequencing, neurodevelopment,  
57 loss-of-function

58

## 59 **Introduction**

60 Schizophrenia (SCZ) is a severe psychiatric disorder that profoundly affects cognitive, behavior  
61 and emotional processes, yet its etiology and pathophysiology are still largely unknown. The  
62 high heritability of SCZ suggests that genetic risk factors contribute to a significant proportion of  
63 the etiology<sup>1,2</sup>. However, the marked reduction in fecundity in SCZ patients suggests the  
64 removal of risk variants with the largest effects from the population by natural selection. Thus  
65 these variants often occur *de novo*. Indeed, the strongest genetic risk factors for SCZ identified  
66 so far are *de novo* large copy number variants (CNV)<sup>3</sup>.

67 The availability of next-generation sequencing permits the detection of *de novo* mutation (DNM)  
68 events at the genome level. Through large-scale sequencing in parent-offspring trios, DNM have  
69 been increasingly discovered from an array of severe neurodevelopmental disorders, including  
70 Autism Spectrum Disorders (ASD)<sup>4</sup>, Attention-Deficit Hyperactivity Disorder (ADHD)<sup>5</sup> and  
71 epileptic encephalopathy<sup>6</sup>. For SCZ, Xu *et al.* showed a large excess of *de novo* nonsynonymous  
72 changes and DNMs presented with greater potential to affect protein structures and functions in  
73 SCZ patients<sup>7</sup>; Girard *et al.* reported increased exonic DNM rate in SCZ patients<sup>8</sup>; and Fromer  
74 *et al.* found that DNMs in SCZ implicated synaptic networks and DNM-affected genes in SCZ  
75 overlapped with those mutated in other neurodevelopmental disorders<sup>9</sup>. Whole exome  
76 sequencing (WES) was applied predominantly in DNM identification thus far, however, few  
77 DNM studies have been based on whole genome sequencing (WGS) as WES remains a cost-  
78 effective strategy.

79 However, only 1.22% of DNMs are within exonic regions<sup>10</sup> and meaningful mutations may  
80 occur outside of exons, such as in regulatory elements (i.e. transcriptional promoters, enhancers  
81 and suppressors) thereby altering expression level of governed genes. Similarly, mutations

82 within exon-intron junction regions may influence splice sites and thus lead to inappropriate  
83 expression of particular isoforms<sup>11</sup>. Takata *et al.* reported that cis-acting splicing quantitative  
84 trait loci from prefrontal cortices of human were in linkage disequilibrium with SCZ genome-  
85 wide association study (GWAS) loci and DNMs near splicing sites were enriched in SCZ  
86 patients as compared to controls<sup>12, 13</sup>. Emerging roles of non-coding RNAs such as microRNA,  
87 circRNA and lncRNA further call for attention to explore DNMs in non-coding regions.

88 We therefore conducted WGS on two cohorts of Chinese families with matched patient-sibling  
89 to capture all classes of DNMs and to more fully describe the genetic architecture of SCZ. This  
90 study was conducted to identify potential DNMs in SCZ in the Asian population, adding to the  
91 growing body of information regarding ethnicity-specific DNMs.

## 92 **Methods**

### 93 *Subjects*

94 Subjects were drawn from two distinct cohorts, Taiwan and Shanghai, of Han Chinese origin.  
95 Recruitment of subjects from the Taiwan cohort was described in previous publications<sup>14, 15</sup>. The  
96 rationale for combining the two cohorts was to increase the power to detect DNMs because each  
97 of the two cohorts has small sample size but they are ethnically homogeneous. Briefly, families  
98 with at least three siblings, two of whom were diagnosed with SCZ, were recruited in the Taiwan  
99 Schizophrenia Linkage Study (TSLs) from 1998 to 2002. All recruited subjects were  
100 interviewed using the Diagnostic Interview for Genetic Studies (DIGS)<sup>16</sup>, accompanied with the  
101 Family Diagnostic Interview for Genetic Studies (FIGS)  
102 (<https://www.nimhgenetics.org/resources/clinical-instruments/figs/list-of-figs>). Final diagnostic  
103 assessment was based on the criteria of the fourth edition of the Diagnostic and Statistical

104 Manual (DSM-IV), joined with the record of DIGS, FIGS, interviewer notes, and hospital  
105 anamnesis. For the Shanghai cohort, families from the Bio-x SCZ Biobank with at least three  
106 siblings, two of whom were diagnosed with SCZ, were selected. All families from the Bio-x SCZ  
107 Biobank were recruited from the city of Shanghai and the provinces of Hebei, Liaoning and  
108 Guangxi from 2001 to 2003. All individuals with SCZ were interviewed by two independent  
109 psychiatrists and diagnosed according to DSM-IV criteria. A total of 23 families (10 from  
110 Taiwan and 13 from Shanghai), with SCZ patients, matched unaffected siblings and parents,  
111 were used in this study (Figure 1). For detailed demographic characteristics of all individuals in  
112 the 23 families, please refer to Supplementary Table S1. All subjects gave written informed  
113 consent with the approval of the local research ethics committees.

#### 114 ***Whole genome sequencing***

115 For the subjects of Taiwan cohort, whole blood samples were collected with anticoagulant  
116 (EDTA) tubes and sent to the National Institute of Mental Health (NIMH) Repository and  
117 Genomics Resource (RGR). Lymphocytes from the whole blood samples were transformed into  
118 immortalized lymphoblastoid cell lines and stored. The DNA samples extracted from the cell  
119 lines were used for WGS. WGS was carried out on the Illumina HiSeq 2000 platform using  
120 paired-end chemistry with 75 base-pair read length through NovoGene, Inc. (Beijing, China). For  
121 detailed description please refer to previous publication<sup>17</sup>. WGS data for the subjects of Taiwan  
122 cohort can be accessed in BioProject of NCBI:

123 <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA551447>. For the subjects from Shanghai cohort,  
124 whole blood samples were also collected with anticoagulant tubes. DNA was extracted from  
125 blood lymphocytes by standard procedures using FlexiGene DNA kits (Fuji, Tokyo, Japan).  
126 DNA libraries were prepared using protocols recommended by Illumina (Illumina, San Diego,

127 CA). WGS was performed on Illumina HiSeq-X Ten platform with 150 base-pair read length  
128 through Cloud Health Genomics Ltd. (Shanghai, China).

### 129 *Quality control and variant calling*

130 FastQC (v0.11.8) was used to perform quality checks on all samples across Taiwan and Shanghai  
131 cohorts (Supplementary Figure S1).

132 The GATK best practices of variant calling were applied to process all raw reads from both  
133 Taiwan and Shanghai cohorts<sup>18</sup>. Raw sequencing reads in FASTQ format were aligned to the  
134 GRCh37 build of the human reference genome with BWA-mem<sup>19</sup>. Then the aligned reads in  
135 BAM format were sorted, indexed and marked with duplicate reads with Picard Tools. Reads  
136 containing indels were realigned with GATK's IndelRealigner tool. Next, GATK was used to  
137 perform Base Quality Score Recalibration (BQSR). Quality control after alignment was  
138 performed using Picard (v2.20.4) CollectAlignmentSummaryMetrics (Supplementary Table S2).  
139 Variant calling was performed across all samples with GATK (v4.1.1.0) HaplotypeCaller. For  
140 detailed variant calling pipeline, please refer to Supplementary Figure S2. To further  
141 systematically remove potentially false positively called variants, we applied the following  
142 quality filters for each variant: (1) the quality score normalized by allele depth is less than 2; (2)  
143 the root mean square of the mapping quality is less than 40; (3) the strand bias is more than 60;  
144 (4) three consecutive variants were clustered within 10 bases; and (5) the FILTER tag is not  
145 PASS.

### 146 *Kinship analysis, DNM calling and annotation*

147 We used PLINK to perform kinship analysis<sup>20</sup>. Briefly, for a given family, if the father was  
148 shown to be within the third degree relative to the mother, the family would be excluded; if the  
149 child was not shown to be the first degree relative to the parents, the child would be excluded.  
150 To ensure the DNM calls with high confidence, three tools, GATK PhyseByTransmission (PBT),  
151 TrioDeNovo (v0.0.6) and DeNovoGear (v.develop), were used to evaluate the calls<sup>21-23</sup>. Only  
152 DNMs called by all three tools consistently were considered as candidate DNMs.

153 PBT was run with the following command:

```
154 java -jar GenomeAnalysisTK.jar -T PhaseByTransmission -R human_g1k_v37_decoy.fasta -V  
155 parent_child_trio.vcf -prior 1.0e-8 -mvf PBT_result.vcf
```

156 TrioDeNovo was run with the following command:

```
157 triodenovo --ped parent_child_pedigree.ped --in_vcf parent_child_trio.vcf --mu 1.0e-8 --out_vcf  
158 TrioDeNovo_result.vcf
```

159 DeNovoGear was run with the following command:

```
160 dng dnm --ped parent_child_pedigree.ped -vcf parent_child_trio.vcf -s 1.0e-8 --write  
161 DeNovoGear_result.vcf
```

162 After obtaining consistently called DNMs, the following five criteria were applied to retain high  
163 quality calls tagged with PASS in the FILTER annotation: (1) quality score is greater than or  
164 equal to 30; (2) genotypes of the parents are homozygotes; (3) genotype of the child is  
165 heterozygote; (4) phred-scaled maximum likelihood of heterozygote for the parents is less than  
166 50; and (5) phred-scaled maximum likelihood of heterozygote of the child is 0. DNMs with MAF



167 greater than 0.01 in East Asian populations were further excluded by querying gnomAD  
168 (<https://gnomad.broadinstitute.org/>) and EXac (<http://exac.broadinstitute.org/>). Please refer to  
169 Supplementary Figure S2 for detailed pipeline of DNM calling and Supplementary Figure S3 for  
170 the distributions of DNM quality scores. Remaining DNMs were annotated using ANNOVAR<sup>24</sup>.

### 171 ***Polymerase chain reaction (PCR)-based Sanger sequencing validation***

172 For the families where candidate DNMs were found, DNA from all members of the family was  
173 subjected to PCR-based Sanger sequencing by capillary electrophoresis according to standard  
174 molecular biology practices (ABI 3130 genetic analyzer, ThermoFisher Scientific). Primer3Plus  
175 was used to design the PCR primers<sup>25</sup>. For the *GJCI* mutation, the forward primer sequence was  
176 5'-TTAGGTTTGGGTTGGCTCTG -3' and the reverse primer sequence was 5'-  
177 CACGGTGAAGCAGACAAGAA -3'. For the *HIST1H2AD* insertion, the forward primer  
178 sequence was 5'-CTCGTTTACTTGGCCCTTGG -3' and the reverse primer sequence was 5'-  
179 ACAACAAGAAGACCCGCATC -3'.

180 Reactions were performed on an Eppendorf MasterCycler (Eppendorf North America, New York,  
181 USA) under the following cycling conditions: denaturation at 95 °C for 3 min, 35 cycles of  
182 95 °C for 15 sec, 55 °C for 20 sec, 72 °C for 30 sec, and a final extension at 72 °C for 5 min.  
183 Sanger sequencing data was then analyzed using Chromas software  
184 (<https://technelysium.com.au/wp/>).

### 185 ***Identification of genes implicated by coding DNMs in SCZ***

186 As the spontaneous background mutation rates vary greatly between genes, those carrying  
187 relatively more protein-coding DNMs in cases are not necessarily implicated by DNMs<sup>26</sup>. To  
188 identify those genes implicated by protein-coding DNMs or of which the DNMs occurred higher

189 than the background mutation rates, the R package denovolyzeR was used to analyze protein-  
190 coding DNMs based on a mutation model developed previously<sup>26</sup>. Briefly, denovolyzeR  
191 estimates underlying mutation rate based on trinucleotide context and incorporates exome depth  
192 and divergence adjustments based on macaque-human comparisons over a  $\pm$  1-Mb window and  
193 accommodates known mutational biases, such as CpG hotspots. By applying the underlying  
194 mutation rate estimates, denovolyzeR generates prior probabilities for observing a specific  
195 number and class of mutations (synonymous, missense, nonsense, splice-site and frameshift) for  
196 a given gene.

197 To validate whether the genes implicated by coding DNMs were also implicated by rare variants,  
198 the population-based SCZ Swedish case-control cohort with whole exome sequences and  
199 variants called were used to perform the analysis<sup>27</sup>. Variants with MAF greater than 0.01 were  
200 excluded and only rare variants were retained subsequently. The association between the set of  
201 rare variants from Swedish case-control cohort located in the exons of a given gene implicated  
202 by coding DNM and phenotype was tested using SKAT<sup>28</sup>.

### 203 *DNM burden test*

204 To determine whether some genes carry more DNMs in SCZ patients than expected by chance,  
205 we performed the DNM burden test for each gene potentially implicated by DNM. Human brain-  
206 specific gene enhancer information was included from PsychENCODE  
207 (<http://resource.psychencode.org/>) and human-specific gene promoter information from  
208 Eukaryotic Promoter Database (EPD, <https://epd.epfl.ch//index.php>)<sup>29, 30</sup>. For a given gene,  
209 DNMs occurring in its gene body, which includes both exons and introns, brain-specific gene  
210 enhancer and gene promoter regions were considered as burdens. For a given gene, we compared  
211 the number of DNMs mapped to these regions in SCZ patients with the number of DNMs

212 mapped to these regions in unaffected siblings, and then assessed the significance of the  
213 comparison using 10,000 within-sibship case-control label-swapping permutations.  $P$  value was  
214 calculated as the proportion of permutations with relative risk (RR) as or more extreme than in  
215 the observed data.

### 216 *Developmental expression of DNM-implicated genes*

217 Multiple lines of evidence have shown that prenatal maternal infection, malnutrition and stress  
218 are risk factors for SCZ<sup>31-33</sup>. The neurodevelopmental model of SCZ posits that a perturbation in  
219 early brain development leads to an altered brain developmental trajectory that is sensitive to  
220 molecular changes associated with development and environmental experience, consequently  
221 converging on the emergence of SCZ in early adulthood<sup>34</sup>. It was hypothesized that DNMs  
222 drove dysfunction of genes in early brain development and that this dysfunction confers risks for  
223 subsequent SCZ. To determine whether DNM-implicated genes (loss-of-function DNM genes  
224 and DNM-burdened genes) were involved in early brain development, human brain  
225 developmental expression data from BrainCloud and BrainSpan was evaluated<sup>35, 36</sup>. The  
226 expression data of BrainCloud consisted of data derived from the prefrontal cortices of 269  
227 individuals<sup>35</sup>, whereas the expression data of BrainSpan consisted of 42 brain specimens across  
228 13 developmental states in 8-16 brain structures<sup>36</sup>. BrainCloud expression data was examined by  
229 comparing the expression of a DNM gene in prenatal stage to the expression in postnatal stage  
230 and BrainSpan expression data was evaluated by leveraging the developmental effect scores  
231 curated in a previous publication<sup>37</sup>. A developmental effect score measures the effect of age on  
232 expression per gene per brain structure, with a higher developmental effect score of a gene in a  
233 given brain structure indicating a stronger involvement of brain development in that structure. By  
234 10,000 gene label-swapping permutation,  $P$  value of a DNM gene for a given brain structure was

235 calculated as the proportion of permutations with developmental effect scores as or more  
236 extreme than the observed value. DNM genes were then further evaluated in brain developmental  
237 expression data from other species (macaque and mouse)<sup>38,39</sup>.

### 238 *Genetic susceptibilities of DNM-implicated genes in SCZ and SCZ-related traits*

239 To determine whether DNM-implicated genes are among the loci found by the genome-wide  
240 association study (GWAS) of SCZ or SCZ-related traits, we used GWAS summary statistics  
241 from SCZ<sup>1</sup>, ASD<sup>40</sup>, ADHD<sup>41</sup>, bipolar disorder (BD)<sup>42</sup>, major depressive disorder (MDD)<sup>43</sup>,  
242 intelligence<sup>44</sup>, educational attainment (EA)<sup>45</sup>, cognitive performance (CP)<sup>45</sup>, and smoking and  
243 drinking<sup>46</sup>. The criterion for annotating a single nucleotide polymorphism (SNP) to a given gene  
244 was that the GWAS SNP is located within 10 kb of the gene boundaries.

### 245 *Co-expression and enrichment analysis*

246 To explore the potential functions or pathological pathways affected by DNM-implicated genes,  
247 expression data from BrainCloud was leveraged by retrieving genes highly co-expressed with the  
248 candidate DNM genes. To identify enrichments in gene ontologic features, biological pathways,  
249 diseases and drug targets, WebGestalt was used (<http://www.webgestalt.org/>)<sup>47</sup>. In WebGestalt,  
250 genes co-expressed with the candidate DNM gene were input as the target gene set and all genes  
251 in the BrainCloud expression data were input as the reference gene set. Enrichments with B-H  
252 FDR-corrected *P* values less than 0.05 were considered significantly enriched.

### 253 *Cell-type specific expression analysis*

254 To examine cell-type specific expression of DNM-implicated genes, brain tissue single nucleus  
255 RNA-seq (snRNA-seq) data of middle temporal gyrus (MTG), of which the cells have been sub-  
256 typed from Allen Brain Atlas (<https://celltypes.brain-map.org/rnaseq>) and single cell expression

257 data from PsychENCODE were utilized. Single cell expression data from PsychENCODE were  
258 merged from multiple brain regions, including frontal cortex, visual cortex and cerebellar  
259 hemisphere<sup>48</sup>. Raw read count data was normalized by log-transformation using R package  
260 Seurat<sup>49</sup>. For a given DNM gene, the dominant cell type(s) with high expression were  
261 determined by pair-wise Wilcoxon test.

262

## 263 **Results**

264 The goal of our study was to identify DNM disturbed genes, of which the dysfunctions can  
265 contribute to the pathogenesis of SCZ. We identified coding DNM-implicated genes and genes  
266 carrying more DNM burdens in SCZ patients than their unaffected siblings. These DNM-  
267 implicated genes were potentially detrimental and subsequent analyses were performed to  
268 explore their pathological effects (Figure 1).

### 269 *Identification of DNMs and genes implicated by DNMs*

270 To ensure parental unrelatedness and that the children are indeed biological offspring of their  
271 parents, kinship analysis was performed for each individual family. For the Taiwan cohort, one  
272 family (Family ID: 35-04560) was excluded as the father is within the third degree relative of the  
273 mother, one family (Family ID: 35-93405) was excluded as the father was not found to be related  
274 to any of the children and one child in one family was excluded as he was found to be unrelated  
275 to his parents (Individual ID: 35-02497-01) (Supplementary Table S1). Three children from  
276 Shanghai cohort were excluded as they were unrelated to their respective parents (Individual IDs:  
277 CHG000225, CHG000236 and CHG000246) (Supplementary Table S1). A total of 21 families  
278 were retained for analyses. For detailed information of the families recruited and the individuals

279 in each family in the Taiwan and Shanghai cohorts and the families or individuals excluded due  
280 to unrelatedness, please refer to Supplementary Table S1.

281 In this study,  $70.71 \pm 6.83$  *de novo* point mutations and  $6.31 \pm 3.64$  *de novo* indel mutations with  
282 high confidence per individual were identified. The observed *de novo* point mutation rate of  
283  $1.145 \times 10^{-8}$  was consistent with the neutral expectation of  $1.140 \times 10^{-8}$  ( $P = 0.95$ , two-sided  
284 exact binomial test)<sup>23</sup>. The observed *de novo* indel mutation rate of  $1.022 \times 10^{-9}$  was consistent  
285 with the neutral expectation of  $1.420 \times 10^{-9}$  ( $P = 0.500$ , two-sided exact binomial test)<sup>23</sup>. All  
286 DNMs were checked visually by Integrative Genomics Viewer (IGV). Overall, the DNMs  
287 occurred in non-coding regions predominantly in intergenic regions (Supplementary Figure S4).  
288 No obvious difference was observed between unaffected siblings and SCZ patients with regards  
289 to the distributions of DNM locations relative to genes (Supplementary Figure S4). No obvious  
290 differences were observed between unaffected siblings and SCZ patients with regards to the  
291 percentages of DNMs occurring in exons (unaffected siblings: 29.85% versus SCZ patients:  
292 30.29%) and introns (unaffected siblings: 1.53% versus SCZ patients: 2.03%). The  
293 nonsynonymous-to-synonymous ratio in SCZ patients was not found to be different from the  
294 ratio in unaffected siblings<sup>50</sup>, which might be attributed to the limited sample size. Two  
295 nonsense loss-of-function DNMs implicating *GJCI* and *HIST1H2AD* respectively were  
296 identified in SCZ patients (Table 1 and Supplementary Table S4). The two loss-of-function  
297 DNMs were visually verified by IGV (Supplementary Figure S5 and S6) and then were  
298 confirmed by Sanger sequencing (Supplementary Figure S7 and S8). To examine whether the  
299 occurrence rates of nonsense loss-of-function DNMs in *GJCI* and *HIST1H2AD* in SCZ patients  
300 were higher than expected by chance, we compared the nonsense mutation probabilities of *GJCI*  
301 and *HIST1H2AD* to those of all genes calculated in Samocha *et al.*<sup>51</sup>. Nonsense DNMs were not

302 prone to occur in DNA regions of *GJCI* and *HIST1H2AD* (Supplementary Figure S9). No loss-  
303 of-function DNMs were identified in unaffected siblings on the whole genome scale  
304 (Supplementary Table S3).

305 Except for the two nonsense loss-of-function DNMs, we also investigated other DNMs in coding  
306 regions to find damaging DNMs because DNMs occurring in coding regions may change protein  
307 structures physically (Figure 1 and Supplementary Table S3). A detailed list of these DNMs are  
308 shown in Supplementary Table S4. To identify genes implicated by these protein-coding DNMs,  
309 denovolyzeR was used. Due to the relatively small sample size of this study, Bonferroni  
310 correction was used to reduce the false discovery rate. Only *GJCI* and *HIST1H2AD* carrying  
311 nonsense DNMs were significantly identified to be implicated by DNMs (Supplementary Table  
312 S5). We applied another background mutation rate-based model, referred to as the chimpanzee-  
313 human divergence model, which also showed *GJCI* and *HIST1H2AD* were significantly  
314 implicated by the nonsense DNMs ( $P$  value =  $1.56 \times 10^{-5}$  for *GJCI* and  $P$  value =  $1.82 \times 10^{-5}$  for  
315 *HIST1H2AD*)<sup>52</sup>. Of note, the *GJCI* nonsense DNM was predicted to be extremely close to the  
316 most severe 0.1% of mutations by combined annotation dependent depletion (CADD)  
317 (Supplementary Table S4; mutations with CADD phred-like scores greater than or equal to 30 is  
318 the most severe 0.1% of mutations)<sup>53</sup>. Moreover, *GJCI* falls into the haploinsufficient category  
319 with a high probability of loss-of-function intolerance (pLI) of 0.94, therefore is extremely  
320 intolerant of loss-of-function variation<sup>54</sup>.

321 To investigate whether *GJCI* and *HIST1H2AD* were also implicated by rare variants as DNMs in  
322 SCZ, we analyzed SCZ Swedish case-control cohort comprised of 4969 SCZ patients and 6245  
323 controls. Rare variants in the exons of *GJCI* were significantly associated to SCZ (Table 2).

324 ***Identification of genes burdened with DNMs in SCZ patients***

325 Previous studies have shown that 99% of the DNMs occurred in non-coding regions<sup>10</sup>. DNMs  
326 occurring in regulatory regions can potentially disturb the bindings of transcriptional factors and  
327 thus influence gene expression. If a gene or regulatory regions of the gene carry more DNMs in  
328 SCZ patients than their unaffected siblings, this gene may have a role in disease predisposition.  
329 Based on this assumption, for a given gene, we compared the number of DNMs that occurred in  
330 brain-specific enhancer, promoter and gene body in SCZ patients to the number of DNMs in  
331 unaffected siblings by within-sibship case-control label-swapping permutation. Before  
332 calculation, to reduce the falsely identified genes by chance, we excluded genes with low total  
333 DNM counts in both SCZ patients and unaffected siblings ( $\leq 3$ ). Due to the relatively small  
334 sample size, Bonferroni correction was used to reduce the false discovery rate. Ten genes,  
335 *DPYSL2*, *NBPF1*, *SDK1*, *ZNF595*, *ZNF718*, *GCNT2*, *SNX9*, *AACS*, *KCNQ1* and *MSI2*, were  
336 identified to carry more DNMs in SCZ patients than their unaffected siblings. Multiple DNMs  
337 implicated enhancers for *DPYSL2*, *NBPF1*, *SNX9* and *MSI2* (Supplementary Table S6),  
338 suggesting the dysregulation of these genes may predispose an individual to SCZ. One single  
339 enhancer can regulate the expression of multiple genes. Therefore, single DNM implicating an  
340 individual enhancer can disturb the expression of multiple genes. We leveraged transcription  
341 factor (TF)-enhancer-target gene linkage data from PsychENCODE to establish the gene  
342 regulatory network disturbed by the DNMs implicating the enhancers identified by DNM burden  
343 test (Figure 2). For detailed list of the DNMs found in the ten genes reported here, please refer to  
344 Supplementary Table S6. Interestingly, no DNM occurred in promoters of the ten genes.

345 ***DNMs occurred in genes involving in early brain development***



346 In the following analyses, coding DNM-implicated genes (*GJCI* and *HIST1H2AD*,  
347 Supplementary Table S5) and DNM-burdened genes (Table 3) were as assumed to be  
348 detrimental DNM genes to explore their potential functions that might be related to SCZ.  
349 Early neurodevelopmental events have been implicated in the pathogenesis of SCZ<sup>34</sup>. Genes  
350 implicated in SCZ function in processes important to fetal brain development<sup>50, 55</sup>. To determine  
351 whether the detrimental DNM genes, including *GJCI* and *HIST1H2AD* implicated by nonsense  
352 mutations (Supplementary Table S5) and genes carrying more DNMs in SCZ patients (Table 3),  
353 were involved in brain development, we leveraged the developmental expression data of  
354 prefrontal cortices (PFC), one of the most highly implicated brain regions in SCZ, from  
355 BrainCloud. Nine of the 13 detrimental DNM genes, including the two loss-of-function DNM-  
356 implicated genes *GJCI* and *HIST1H2AD*, and seven DNM-burdened genes *DPYSL2*, *NBPF1*,  
357 *SDK1*, *ZNF595*, *ZNF718*, *KCNQ1* and *SNX9*, showed biased higher expression in prenatal stage  
358 compared to that of the expression in postnatal stage (Figure 3). The large proportion of 9/12  
359 potentially detrimental DNM genes with higher expression in prefrontal cortices was more than  
360 expected by chance (Supplementary Figure S10,  $P = 0.05$ , hypergeometric test). We next sought  
361 to examine whether the involvements of detrimental DNM genes in PFC development were  
362 preserved in other brain regions. The genes with available developmental data in BrainSpan were  
363 analyzed. It was found that *GJCI*, *SDK1* and *GCNT2* were still involved in the developments of  
364 other brain regions (Supplementary Figure S11). To examine whether the involvements of  
365 detrimental DNM genes in human brain development were conserved across species, we first  
366 queried the brain developmental expression data of macaque, a primate species evolutionarily  
367 close to *Homo sapiens*. Only DNM genes with expression data of macaque were analyzed. *GJCI*,  
368 *HIST1H2AD*, *DPYSL2*, *SDK1* and *MSI2* showed higher expression in prenatal stage than the

369 expression in postnatal stage (Supplementary Figure S12). We then queried the brain  
370 developmental expression data of mouse. Since the developmental data of mouse were limited in  
371 postnatal stage, we applied linear regression to examine the change of DNM gene expression  
372 level with time. The expression levels of *GJCI*, *DPYSL2*, *SDK1* and *AACS* significantly  
373 decreased with time (Supplementary Figure 13), which implied their involvements in prenatal  
374 neurodevelopment of mouse. Specifically for *GJCI*, Leung et al. showed that *GJCI* displayed  
375 high expression in embryonic stage followed by a massive postnatal decrease in the rat midbrain-  
376 floor, where dopaminergic neurons were mostly populated <sup>56</sup>.

### 377 ***Common variants in detrimental DNM genes may influence risks of SCZ-associated traits***

378 To determine whether the detrimental DNM genes are involved more broadly in SCZ, we asked  
379 whether common variants present in the DNM genes confer risk for SCZ and SCZ-associated  
380 traits. We extracted all SNPs that occur within 10 kb of the DNM genes. For a given trait, the  
381 SNP with the minimum *P* value mapped to the gene was used to represent the gene risk on the  
382 trait. Genes with minimum SNP *P* values less than the suggestive threshold of  $1 \times 10^{-5}$  were  
383 considered as risk genes for the trait. We found that the DNM genes influence risk for SCZ-  
384 associated traits, including intelligence, educational attainment, cognitive performance, smoking  
385 and drinking primarily (Supplementary Table 7). Of note, *GJCI*, *HIST1H2AD* and *SDK1* confer  
386 risks for multiple SCZ-associated traits with SNPs passed the genome-wide significance  
387 threshold of  $5 \times 10^{-8}$ .

### 388 ***GJCI co-expressed with multiple potassium channel genes and is a potentially target for SCZ***

389 Next, we focused on the loss-of-function DNM gene *GJCI*, a member of the connexin gene  
390 family, which showed strong evidence of SCZ susceptibility (Supplementary Table S8). DNMs

391 in other brain-associated connexin genes were also found in psychiatric patients (Supplementary  
392 Table S9). *GJCI* showed higher expression in prenatal stage than the expression in postnatal  
393 stage in PFC and multiple other brain regions, and its involvement in early brain development  
394 was conserved across species (Figures 3; Supplementary Figures S11, S12 and S13). Moreover,  
395 common variants present in *GJCI* confer risks for intelligence, educational attainment, cognitive  
396 performance and alcohol abuse, which were associated with SCZ (Supplementary Table S7)<sup>57-60</sup>.

397 To explore the pathogenic effects of *GJCI*, we first sought to identify the genes that might be  
398 impacted by the dysfunction of *GJCI*. We performed co-expression analysis with Pearson  
399 correlation coefficient greater than 0.8 or less than -0.8 in PFC to identify these genes (Figure 4A  
400 and supplementary Table S10). Then we leveraged the genes co-expressed with *GJCI* to perform  
401 enrichment analysis to identify functions or pathways involved by *GJCI*. Interestingly, the genes  
402 co-expressed with *GJCI* were enriched in SCZ, SCZ drug zuclopenthixol and SCZ-associated  
403 functions or pathways, including potassium ion transport (Figure 4B and Supplementary Table  
404 S11). Of note, multiple potassium ion channel genes were negatively co-expressed with *GJCI*  
405 (Figure 4A), suggesting their dysfunctions may be subsequent to the dysfunction of *GJCI*.

406 To determine whether the expression of *GJCI* was specific to a certain cell type, we performed  
407 cell type specific analysis of *GJCI* expression. *GJCI* was predominantly expressed in  
408 glutamatergic excitatory neurons (Figure 4C and 4D, refer to Supplementary Tables S12 and S13  
409 for pair-wise *P* values among different cell types derived from Wilcoxon rank sum test). This  
410 should be interesting as glutamatergic dysfunction has long been implicated in SCZ<sup>61</sup>.

411

## 412 Discussion

413 In this study, we used two matched SCZ-sibling family cohorts of Han Chinese origin to  
414 investigate DNMs and DNM-implicated genes in SCZ. By integrating this information with  
415 publicly available data, including brain developmental expression profiles and summary GWAS  
416 statistics, we identified DNM-implicated genes that were involved in fetal neurodevelopment.  
417 These genes may confer risks for SCZ or SCZ-associated traits, and are potential drug therapy  
418 targets for SCZ.

419 Connexin 45 (Cx45) encoded by *GJCI* is a component of the gap junction channel. It is one of  
420 the two connexin genes expressed predominantly in neurons<sup>62</sup>. Our analyses showed that *GJCI*  
421 was expressed highly in prenatal stage as compared to that in postnatal stage and was expressed  
422 predominantly in glutamatergic excitatory neurons in the human brain (Figure 4C and 4D). For  
423 the nonsense mutation identified in our study, its occurrence might trigger the activation of  
424 surveillance pathway nonsense-mediated mRNA decay (NMD), which reduces aberrant proteins  
425 to be formed<sup>63</sup>. The reduction of *GJCI* may perturb the co-expressed genes and thus influence  
426 the potassium ion transport and axon/dendrite formations, especially in early neurodevelopment  
427 (Figure 4A and 4B). Krüger *et al.* reported Cx45-deficient embryos exhibited striking  
428 abnormalities in vascular development and died between embryonic day 9.5 and 10.5<sup>64</sup>. Kumai  
429 *et al.* reported that Cx45-deficient embryos displayed an endocardial cushion defect in early  
430 cardiogenesis and died of heart failure at around embryonic day 9<sup>65</sup>. Nishii *et al.* showed that  
431 mice lacking Cx45 conditionally in cardiac myocytes displayed embryonic lethality and the  
432 requirement of Cx45 for developing cardiac myocytes<sup>66</sup>. These studies indicate the critical role  
433 of Cx45 in embryonic development. Our results showed that *GJCI* displayed biased high  
434 expression across multiple brain regions in prenatal stage, suggesting it is required for  
435 neurodevelopment. The high expression of *GJCI* in prenatal/early stage in other species

436 indicated its involvement in development is phylogenetically conserved. The dysfunction or loss-  
437 of-function can cause lethal effects, thereby such mutation would be eliminated by natural  
438 selection in evolution. Interestingly, all potassium ion channel genes were negatively co-  
439 expressed with *GJCI*. Therefore, the reduction of *GJCI* indicates an increase or overactivity of  
440 potassium channels. Miyake *et al.* reported overexpression of *Ether-a`-go-go* potassium channel  
441 gene *KCNH3* in the forebrain can impair the performances of working memory, reference  
442 memory and attention <sup>67</sup>. Ghelardini *et al.* reported that administrations of potassium channel  
443 openers bring out amnesic effect which can be reversed by potassium channel blockers <sup>68</sup>. This  
444 evidence suggested that the cognitive or memory deficits in this case were caused by the  
445 increased expression of potassium channel genes due to the reduction of *GJCI* activity (Figure 5).  
446 The various connexins of gap junctions may be capable of differentiating between the operation  
447 qualities of the cognate synapses defined by the neurotransmitter types <sup>69</sup>. Mitterauer *et al.* raised  
448 a hypothesis that if the function of glial gap junction proteins is lost, the brain is incapable of  
449 distinguishing between the same and different qualities of information processing and thus cause  
450 severe cognitive impairments in SCZ <sup>69</sup>. Our findings support these hypotheses. Overall, the loss-  
451 of-function of Cx45 may be a driver of pathogenesis for some SCZ cases.

452 *HIST1H2AD*, the other nonsense DNM gene close to HLA locus, encodes the member D in the  
453 histone cluster 1 H2A family. Studies have demonstrated that several SCZ candidate genes are  
454 especially susceptible to changes in transcriptional activity as a result of histone modification <sup>70</sup>,  
455 <sup>71</sup>. Therefore, a deficit in the histone itself can implicate multiple SCZ candidate genes.  
456 Moreover, epigenetic regulation effects of histone deacetylase inhibitors were potentially  
457 suggested to treat SCZ <sup>72</sup>, which implies the fundamental role of histone in the pathology of SCZ.

458 Gene level DNM burden test identified a list of genes carrying more DNMs in SCZ patients than  
459 their unaffected siblings. In the literature, there were experimental or clinical evidences  
460 demonstrating their potential association with SCZ. Luan et al. reported SNPs in *MSI2* are  
461 strongly associated with SCZ in the Chinese population <sup>73</sup>. In the GWAS of PGC, the SNPs in  
462 *MSI2* were also associated with SCZ (Supplementary Table 7). Another DNM-burdened genes,  
463 *DPYSL2*, is a member of the collapsin response mediator protein (CRMP) family. CRMP forms  
464 homo- and hetero-tetramers and facilitates neuron guidance, growth and polarity. It also plays a  
465 role in synaptic signaling through interactions with calcium channels. Lee *et al.* revealed that  
466 *DPYSL2* was downregulated in the PFC and hippocampus of prenatally stressed (PNS) adult rats  
467 that underperformed in behavioral tests <sup>74</sup>. Bruce *et al.* conducted potassium channel-targeted  
468 SNP association analyses with SCZ and SCZ-associated phenotypes. rs8234 in *KCNQ1*, a DNM-  
469 burdened gene in our study, was associated to processing speed <sup>75</sup>. Geschwind *et al.* found that  
470 patients with voltage-gated potassium channel complex antibody (VGKCC-Abs) had particular  
471 impairment in memory and executive functions when they evaluated cognitive function and  
472 imaging data in patients with VGKCC-Abs associated encephalopathy <sup>76</sup>. Interestingly, the  
473 impaired brain functions coincide with the two most implicated brain regions in SCZ,  
474 dorsolateral prefrontal cortex and the hippocampus <sup>77</sup>. This evidence demonstrated the efficacy  
475 of our DNM burden test by incorporating enhancer and promoter regions into consideration. It  
476 also indicated DNMs contributing to the genesis of disease are not limited in coding regions,  
477 underling the value of WGS.

478 Except for *HIST1H2AD*, common variants in these identified DNM genes were not strongly  
479 associated to psychiatric diseases. However, a few of them, *GJC1*, *HIST1H2AD* and *SDK1*, were  
480 strongly associated to SCZ-associated traits, including intelligence, educational attainment,

481 smoking and drinking. It suggested the significance of these DNM genes in neurodevelopment  
482 and that the lethal mutations occurred in these genes were eliminated by marked reduction of  
483 fecundity in psychiatric patients.

484 The results should be interpreted with caution because of limited samples in the pilot study. A  
485 few parents with other mental illness from the Taiwan cohort may complicate the interpretation  
486 of the DNMs if the mental illness shares certain genetic liability with SCZ. Nevertheless, the  
487 association of the nonsense DNM gene *GJCI* with SCZ is deemed reliable: First, the association  
488 of *GJCI* with SCZ is supported by the analyses of rare variants of an independent exome  
489 sequencing dataset where SCZ patients have more rare variants in the gene than controls<sup>27</sup>.  
490 Second, with its intolerance of loss-of-function index of pLI = 0.94, the loss-of-function  
491 mutation is very likely to have detrimental consequences in the regulation of ion channels which  
492 have been implicated in the pathogenesis of SCZ<sup>78,79</sup>. To validate our findings, future studies  
493 with more and independent Chinese family samples are necessary.

494 In summary, we identified a list of DNM-implicated genes which are involved in prenatal  
495 neurodevelopment. Common variants in these DNM-implicated genes had been previously  
496 reported to be associated with SCZ and related traits in previous GWASs, which is consistent  
497 with our analyses. DNMs implicating the enhancers may contribute to pathogenesis of SCZ by  
498 dysregulating the expression of genes. *GJCI* is one of these DNM-implicated genes that is  
499 primarily expressed in glutamatergic neurons and may be involved in the modulation of ion  
500 channel functions, which has also been implicated in SCZ in previous studies<sup>78,79</sup>. Overall, our  
501 study provided new evidence that DNMs have a significant role in SCZ. Further study of these  
502 DNM-implicated genes with functional analyses could lead to better understanding of the  
503 pathology of SCZ.

504

505 **Acknowledgements**

506 This work was supported in part by grants from National Institutes of Health (R01MH101054 to  
507 X.C. and R01LM012806 to Z.Z.), the National Natural Science Foundation of China (grant  
508 81421061), the National Key Research and Development Program (2016YFC0906400),  
509 Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), Cancer Prevention and  
510 Research Institute of Texas (RR180012 to X.J.), and UT Stars award to X.J. The DNA samples  
511 of the subjects from Taiwan cohort were obtained through NIMH Genetics Repository. The  
512 DNA samples of the subjects from Shanghai cohort were from the Bio-x SCZ Biobank in  
513 Shanghai, China. Computational resources from the school of biomedical informatics at The  
514 University of Texas Health Science Center at Houston were used in data analysis. The data from  
515 the TSLs were collected with funding from grant R01MH59624 from K. S. K. and M. T. The  
516 whole genome sequencing of samples from Taiwan cohort were supported by grant from  
517 National Institutes of Mental Health (1R01-MH085560) to M.T. We acknowledge Dr. Hai-Gwo  
518 Hwu and Dr. Wei J. Chen for their recruitment of families, collection of clinical data and  
519 preprocess of blood samples in Taiwan cohort. We acknowledge the help from Dr. Lukas Simon  
520 on single cell analysis and the collection of GWAS summary statistics from Dr. Yulin Dai. We  
521 acknowledge the altruism of the participants and their families and support staff at each of the  
522 participating sites for their contributions to this study.

523

524 **Author contributions**



525 S.J. designed the study, performed the analyses, interpreted the results and wrote the manuscript.  
526 D.Z. collected the demographic data and performed whole genome sequencing, data processing,  
527 quality control and cleaning from Shanghai cohort. Y.W., P.J., C.W., X.L., G.H., D.C., X.J., T.M.  
528 and J.S.W. contributed to data processing, quality control and cleaning. K.S.K. and M.T.  
529 contributed to data collection and whole genome sequencing. J.S.W., Y.L. and J.C. conducted  
530 Sanger sequencing experiment. T.M. revised the manuscript. L.H., J.C., Z.Z., P.J. and X.C.  
531 conceived the project, designed the study, collected the data, interpreted the results and wrote the  
532 manuscript.

533

#### 534 **Conflict of interest**

535 The authors declare that they have no conflict of interest.

536

537 **Figure legends**

538 **Figure 1. Schematic of genetic data processing, DNM identification and functional analysis**  
539 **in 23 families with schizophrenia patients and matched unaffected siblings.** SNV, single  
540 nucleotide variant; INDEL, insertion and deletion.

541 **Figure 2. Gene regulatory network disturbed by the DNMs implicating the enhancers**  
542 **identified by DNM burden test.** Light green arrow nodes are the transcription factors. The  
543 yellow round nodes are the enhancers perturbed by the DNMs. The Orange round nodes are the  
544 genes. The edge between transcription factor and enhancer represent the transcription factor can  
545 bind to the enhancer without the perturbation of DNM. The edge between enhancer and gene  
546 represent the enhancer can enhance the expression of the gene without the perturbation of DNM.  
547 Red labeled genes were those identified by DNM burden test.

548 **Figure 3. Detrimental DNM genes implicated in early brain development in PFC.** A, *GJCI*;  
549 B, *HIST1H2AD*; C, *DPYSL2*; D, *NBPF1*; E, *SDK1*; F, *ZNF595*; G, *ZNF718*; H, *KCNQ1*; I, *SNX9*.  
550 Black dots represent samples from prenatal stage. Blue dots represent samples from postnatal  
551 stage. *P* values were derived from Wilcoxon rank sum test by comparing gene expression from  
552 prenatal stage to postnatal stage.

553 **Figure 4. Genes co-expressed with *GJCI* were enriched in schizophrenia and**  
554 **schizophrenia-associated pathways and drug.** A, *GJCI*-hubed co-expression network. The  
555 nodes of genes positively co-expressed with *GJCI* ( $r_{pearson} > 0.8$ ) were labeled in red and the  
556 nodes of genes negatively co-expressed with *GJCI* ( $r_{pearson} < -0.8$ ) were labeled in blue. The  
557 names of potassium channel genes co-expressed with *GJCI* were marked in red. B, significantly  
558 enriched terms by genes co-expressing with *GJCI*. C. Cell-type specific expression of *GJCI* in

559 the middle temporal gyrus of human brain from Allen Brain Atlas. D. Cell-type specific  
560 expression of *GJCI* in mixed brain regions, including the frontal cortex, visual cortex and  
561 cerebellum hemisphere, from PsychENCODE.

562 **Figure 5. Schematic illustration of possible mechanism of dysfunction of *GJCI* leads to**  
563 **SCZ.** Loss of gap junction formed by connexin 45 blocked the pass of ions and small molecules  
564 between brain cells, which caused the state of homeostatic imbalance in cell. Increased  
565 potassium channel subsequent to the loss of gap junction leads to cognitive impairment and  
566 memory loss in SCZ patients.

567

568

569

570

571

572

573

574

575 **References**

- 576 1. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from  
577 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**(7510): 421-427.
- 578  
579 2. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N *et al.*  
580 Schizophrenia risk from complex variation of complement component 4. *Nature* 2016;  
581 **530**(7589): 177-183.
- 582  
583 3. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS *et al.*  
584 Contribution of copy number variants to schizophrenia from a genome-wide study of  
585 41,321 subjects. *Nat Genet* 2017; **49**(1): 27-35.
- 586  
587 4. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D *et al.* The  
588 contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014;  
589 **515**(7526): 216-221.
- 590  
591 5. Kim DS, Burt AA, Ranchalis JE, Wilmot B, Smith JD, Patterson KE *et al.* Sequencing of  
592 sporadic Attention-Deficit Hyperactivity Disorder (ADHD) identifies novel and  
593 potentially pathogenic de novo variants and excludes overlap with genes associated with  
594 autism spectrum disorder. *Am J Med Genet B Neuropsychiatr Genet* 2017; **174**(4): 381-  
595 389.
- 596  
597 6. Epi KC. De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of  
598 Epileptic Encephalopathies. *Am J Hum Genet* 2016; **99**(2): 287-298.
- 599  
600 7. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S *et al.* Exome sequencing  
601 supports a de novo mutational paradigm for schizophrenia. *Nat Genet* 2011; **43**(9): 864-  
602 868.
- 603  
604 8. Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L *et al.* Increased exonic de  
605 novo mutation rate in individuals with schizophrenia. *Nat Genet* 2011; **43**(9): 860-863.
- 606  
607 9. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P *et al.* De  
608 novo mutations in schizophrenia implicate synaptic networks. *Nature* 2014; **506**(7487):  
609 179-184.
- 610  
611 10. Francioli LC, Polak PP, Koren A, Menelaou A, Chun S, Renkens I *et al.* Genome-wide  
612 patterns and properties of de novo mutations in humans. *Nat Genet* 2015; **47**(7): 822-826.
- 613

- 614 11. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the  
615 decoding machinery. *Nat Rev Genet* 2007; **8**(10): 749-761.
- 616
- 617 12. Takata A, Matsumoto N, Kato T. Genome-wide identification of splicing QTLs in the  
618 human brain and their enrichment among schizophrenia-associated loci. *Nat Commun*  
619 2017; **8**: 14519.
- 620
- 621 13. Takata A, Ionita-Laza I, Gogos JA, Xu B, Karayiorgou M. De Novo Synonymous  
622 Mutations in Regulatory Elements Contribute to the Genetic Etiology of Autism and  
623 Schizophrenia. *Neuron* 2016; **89**(5): 940-947.
- 624
- 625 14. Hwu HG, Faraone SV, Liu CM, Chen WJ, Liu SK, Shieh MH *et al.* Taiwan  
626 schizophrenia linkage study: the field study. *Am J Med Genet B Neuropsychiatr Genet*  
627 2005; **134B**(1): 30-36.
- 628
- 629 15. Faraone SV, Hwu HG, Liu CM, Chen WJ, Tsuang MM, Liu SK *et al.* Genome scan of  
630 Han Chinese schizophrenia families from Taiwan: confirmation of linkage to 10q22.3.  
631 *Am J Psychiatry* 2006; **163**(10): 1760-1766.
- 632
- 633 16. Chen WJ, Hsiao CK, Hsiao LL, Hwu HG. Performance of the Continuous Performance  
634 Test among community samples. *Schizophr Bull* 1998; **24**(1): 163-174.
- 635
- 636 17. Chen J, Wu JS, Mize T, Moreno M, Hamid M, Servin F *et al.* A Frameshift Variant in the  
637 CHST9 Gene Identified by Family-Based Whole Genome Sequencing Is Associated with  
638 Schizophrenia in Chinese Population. *Sci Rep* 2019; **9**(1): 12717.
- 639
- 640 18. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A  
641 *et al.* From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best  
642 practices pipeline. *Curr Protoc Bioinformatics* 2013; **43**: 11 10 11-33.
- 643
- 644 19. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.  
645 *Bioinformatics* 2009; **25**(14): 1754-1760.
- 646
- 647 20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al.* PLINK: a  
648 tool set for whole-genome association and population-based linkage analyses. *Am J Hum*  
649 *Genet* 2007; **81**(3): 559-575.
- 650
- 651 21. Francioli LC, Cretu-Stancu M, Garimella KV, Fromer M, Kloosterman WP, Genome of  
652 the Netherlands *c et al.* A framework for the detection of de novo mutations in family-  
653 based sequencing data. *Eur J Hum Genet* 2017; **25**(2): 227-233.

- 654  
655 22. Wei Q, Zhan X, Zhong X, Liu Y, Han Y, Chen W *et al.* A Bayesian framework for de  
656 novo mutation calling in parents-offspring trios. *Bioinformatics* 2015; **31**(9): 1375-1381.
- 657  
658 23. Ramu A, Noordam MJ, Schwartz RS, Wuster A, Hurles ME, Cartwright RA *et al.*  
659 DeNovoGear: de novo indel and point mutation discovery and phasing. *Nat Methods*  
660 2013; **10**(10): 985-987.
- 661  
662 24. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants  
663 from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**(16): e164.
- 664  
665 25. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an  
666 enhanced web interface to Primer3. *Nucleic Acids Res* 2007; **35**(Web Server issue): W71-  
667 74.
- 668  
669 26. Ware JS, Samocha KE, Homsy J, Daly MJ. Interpreting de novo Variation in Human  
670 Disease Using denovolyzeR. *Curr Protoc Hum Genet* 2015; **87**: 7 25 21-15.
- 671  
672 27. Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J *et al.* Rare loss-of-function  
673 variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat*  
674 *Neurosci* 2016; **19**(4): 571-577.
- 675  
676 28. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests  
677 for the combined effect of rare and common variants. *Am J Hum Genet* 2013; **92**(6): 841-  
678 853.
- 679  
680 29. Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FCP *et al.* Comprehensive functional  
681 genomic resource and integrative model for the human brain. *Science* 2018; **362**(6420).
- 682  
683 30. Dreos R, Ambrosini G, Perier RC, Bucher P. The Eukaryotic Promoter Database:  
684 expansion of EPDnew and new promoter analysis tools. *Nucleic Acids Res* 2015;  
685 **43**(Database issue): D92-96.
- 686  
687 31. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection,  
688 neurodevelopment and adult schizophrenia: a systematic review of population-based  
689 studies. *Psychol Med* 2013; **43**(2): 239-257.
- 690  
691 32. Susser E, St Clair D, He L. Latent effects of prenatal malnutrition on adult health: the  
692 example of schizophrenia. *Ann N Y Acad Sci* 2008; **1136**: 185-192.
- 693

- 694 33. Khashan AS, Abel KM, McNamee R, Pedersen MG, Webb RT, Baker PN *et al.* Higher  
695 risk of offspring schizophrenia following antenatal maternal exposure to severe adverse  
696 life events. *Arch Gen Psychiatry* 2008; **65**(2): 146-152.
- 697
- 698 34. Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of  
699 schizophrenia. *Nat Rev Neurosci* 2017; **18**(12): 727-740.
- 700
- 701 35. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT *et al.* Temporal dynamics  
702 and genetic control of transcription in the human prefrontal cortex. *Nature* 2011;  
703 **478**(7370): 519-523.
- 704
- 705 36. Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A *et al.* Transcriptional  
706 landscape of the prenatal human brain. *Nature* 2014; **508**(7495): 199-206.
- 707
- 708 37. Grote S, Prufer K, Kelso J, Dannemann M. ABAEnrichment: an R package to test for  
709 gene set expression enrichment in the adult and developing human brain. *Bioinformatics*  
710 2016; **32**(20): 3201-3203.
- 711
- 712 38. Fertuzinhos S, Li M, Kawasawa YI, Ivic V, Franjic D, Singh D *et al.* Laminar and  
713 temporal expression dynamics of coding and noncoding RNAs in the mouse neocortex.  
714 *Cell Rep* 2014; **6**(5): 938-950.
- 715
- 716 39. Bakken TE, Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L *et al.* A comprehensive  
717 transcriptional map of primate brain development. *Nature* 2016; **535**(7612): 367-375.
- 718
- 719 40. Autism Spectrum Disorders Working Group of The Psychiatric Genomics C. Meta-  
720 analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a  
721 novel locus at 10q24.32 and a significant overlap with schizophrenia. *Mol Autism* 2017; **8**:  
722 21.
- 723
- 724 41. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E *et al.* Discovery of  
725 the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat*  
726 *Genet* 2019; **51**(1): 63-75.
- 727
- 728 42. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V *et al.* Genome-  
729 wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet* 2019;  
730 **51**(5): 793-803.
- 731
- 732 43. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A *et al.*  
733 Genome-wide association analyses identify 44 risk variants and refine the genetic  
734 architecture of major depression. *Nat Genet* 2018; **50**(5): 668-681.

- 735  
736 44. Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA *et al.* Genome-  
737 wide association meta-analysis in 269,867 individuals identifies new genetic and  
738 functional links to intelligence. *Nat Genet* 2018; **50**(7): 912-919.
- 739  
740 45. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M *et al.* Gene discovery and  
741 polygenic prediction from a genome-wide association study of educational attainment in  
742 1.1 million individuals. *Nat Genet* 2018; **50**(8): 1112-1121.
- 743  
744 46. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F *et al.* Association studies of up to  
745 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol  
746 use. *Nat Genet* 2019; **51**(2): 237-244.
- 747  
748 47. Wang J, Vasaiakar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive,  
749 powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res*  
750 2017; **45**(W1): W130-W137.
- 751  
752 48. Lake BB, Chen S, Sos BC, Fan J, Kaeser GE, Yung YC *et al.* Integrative single-cell  
753 analysis of transcriptional and epigenetic states in the human adult brain. *Nat Biotechnol*  
754 2018; **36**(1): 70-80.
- 755  
756 49. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell  
757 transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol*  
758 2018; **36**(5): 411-420.
- 759  
760 50. Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y *et al.* De novo gene  
761 mutations highlight patterns of genetic and neural complexity in schizophrenia. *Nat*  
762 *Genet* 2012; **44**(12): 1365-1369.
- 763  
764 51. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM *et al.* A  
765 framework for the interpretation of de novo mutation in human disease. *Nat Genet* 2014;  
766 **46**(9): 944-950.
- 767  
768 52. O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG *et al.* Multiplex  
769 targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.  
770 *Science* 2012; **338**(6114): 1619-1622.
- 771  
772 53. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general  
773 framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*  
774 2014; **46**(3): 310-315.
- 775



- 776 54. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T *et al.* Analysis of  
777 protein-coding genetic variation in 60,706 humans. *Nature* 2016; **536**(7616): 285-291.
- 778
- 779 55. Gilman SR, Chang J, Xu B, Bawa TS, Gogos JA, Karayiorgou M *et al.* Diverse types of  
780 genetic variation converge on functional gene networks involved in schizophrenia. *Nat*  
781 *Neurosci* 2012; **15**(12): 1723-1728.
- 782
- 783 56. Leung DS, Unsicker K, Reuss B. Expression and developmental regulation of gap  
784 junction connexins cx26, cx32, cx43 and cx45 in the rat midbrain-floor. *Int J Dev*  
785 *Neurosci* 2002; **20**(1): 63-75.
- 786
- 787 57. Aukes MF, Alizadeh BZ, Sitskoorn MM, Kemner C, Ophoff RA, Kahn RS. Genetic  
788 overlap among intelligence and other candidate endophenotypes for schizophrenia. *Biol*  
789 *Psychiatry* 2009; **65**(6): 527-534.
- 790
- 791 58. Le Hellard S, Wang Y, Witoelar A, Zuber V, Bettella F, Hugdahl K *et al.* Identification  
792 of Gene Loci That Overlap Between Schizophrenia and Educational Attainment.  
793 *Schizophr Bull* 2017; **43**(3): 654-664.
- 794
- 795 59. Liddle PF. Schizophrenic syndromes, cognitive performance and neurological  
796 dysfunction. *Psychol Med* 1987; **17**(1): 49-57.
- 797
- 798 60. Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthoj C. Association between alcohol,  
799 cannabis, and other illicit substance abuse and risk of developing schizophrenia: a  
800 nationwide population based register study. *Psychol Med* 2017; **47**(9): 1668-1677.
- 801
- 802 61. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. *Arch Gen*  
803 *Psychiatry* 1995; **52**(12): 998-1007.
- 804
- 805 62. Yamasaki RJC, Neuroimmunology E. Connexins in health and disease. 2018; **9**: 30-36.
- 806
- 807 63. Hug N, Longman D, Caceres JF. Mechanism and regulation of the nonsense-mediated  
808 decay pathway. *Nucleic Acids Res* 2016; **44**(4): 1483-1495.
- 809
- 810 64. Kruger O, Plum A, Kim JS, Winterhager E, Maxeiner S, Hallas G *et al.* Defective  
811 vascular development in connexin 45-deficient mice. *Development* 2000; **127**(19): 4179-  
812 4193.
- 813
- 814 65. Kumai M, Nishii K, Nakamura K, Takeda N, Suzuki M, Shibata Y. Loss of connexin45  
815 causes a cushion defect in early cardiogenesis. *Development* 2000; **127**(16): 3501-3512.

- 816  
817 66. Nishii K, Kumai M, Egashira K, Miwa T, Hashizume K, Miyano Y *et al.* Mice lacking  
818 connexin45 conditionally in cardiac myocytes display embryonic lethality similar to that  
819 of germline knockout mice without endocardial cushion defect. *Cell Commun Adhes*  
820 2003; **10**(4-6): 365-369.
- 821  
822 67. Miyake A, Takahashi S, Nakamura Y, Inamura K, Matsumoto S, Mochizuki S *et al.*  
823 Disruption of the ether-a-go-go K<sup>+</sup> channel gene BEC1/KCNH3 enhances cognitive  
824 function. *J Neurosci* 2009; **29**(46): 14637-14645.
- 825  
826 68. Ghelardini C, Galeotti N, Bartolini A. Influence of potassium channel modulators on  
827 cognitive processes in mice. *Br J Pharmacol* 1998; **123**(6): 1079-1084.
- 828  
829 69. Mitterauer B. Loss of function of glial gap junctions may cause severe cognitive  
830 impairments in schizophrenia. *Med Hypotheses* 2009; **73**(3): 393-397.
- 831  
832 70. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. *Nat*  
833 *Rev Neurosci* 2005; **6**(4): 312-324.
- 834  
835 71. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M *et al.* GABAergic  
836 dysfunction in schizophrenia: new treatment strategies on the horizon.  
837 *Psychopharmacology (Berl)* 2005; **180**(2): 191-205.
- 838  
839 72. Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S. Epigenetic dysregulation in  
840 schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. *Eur Arch*  
841 *Psychiatry Clin Neurosci* 2013; **263**(4): 273-284.
- 842  
843 73. Luan Z, Lu T, Ruan Y, Yue W, Zhang D. The Human MSI2 Gene is Associated with  
844 Schizophrenia in the Chinese Han Population. *Neurosci Bull* 2016; **32**(3): 239-245.
- 845  
846 74. Lee H, Joo J, Nah SS, Kim JW, Kim HK, Kwon JT *et al.* Changes in Dpysl2 expression  
847 are associated with prenatally stressed rat offspring and susceptibility to schizophrenia in  
848 humans. *Int J Mol Med* 2015; **35**(6): 1574-1586.
- 849  
850 75. Bruce HA, Kochunov P, Paciga SA, Hyde CL, Chen X, Xie Z *et al.* Potassium channel  
851 gene associations with joint processing speed and white matter impairments in  
852 schizophrenia. *Genes Brain Behav* 2017; **16**(5): 515-521.
- 853  
854 76. Geschwind M, Gelfand J, Irani S, Neuhaus J, Forner S, Bettcher B. Neuropsychological  
855 Profiles Of Voltage-Gated Potassium Channel Complex And Other Autoimmune  
856 Encephalopathies; More Than Memory Impairment (S18. 005). AAN Enterprises 2014.

- 857  
858 77. Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR *et al.*  
859 Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional  
860 connectivity in schizophrenia. *Arch Gen Psychiatry* 2005; **62**(4): 379-386.
- 861  
862 78. Peltola MA, Kuja-Panula J, Liuhanen J, Voikar V, Piepponen P, Hiekkalinna T *et al.*  
863 AMIGO-Kv2.1 Potassium Channel Complex Is Associated With Schizophrenia-Related  
864 Phenotypes. *Schizophr Bull* 2016; **42**(1): 191-201.
- 865  
866 79. Pers TH, Timshel P, Ripke S, Lent S, Sullivan PF, O'Donovan MC *et al.* Comprehensive  
867 analysis of schizophrenia-associated loci highlights ion channel pathways and  
868 biologically plausible candidate causal genes. *Hum Mol Genet* 2016; **25**(6): 1247-1254.
- 869  
870

871

872 **Table 1.** Loss-of-function DNMs identified in schizophrenia patients

Individual ID	Chr <sup>a</sup>	Position (hg19)	Gene	Reference allele	Mutant allele	Mutation type	Amino acid substitution
35-50505-02	17	42,882,819	<i>GJCI</i>	G	A	Nonsense	p.Q123X
35-06277-01	6	26,199,170	<i>HIST1H2AD</i>	A	ACTTTACCCAG	Nonsense	p.V101Afs×2

873 <sup>a</sup>Chr: chromosome.

**Table 2.** Rare variant association tests for the loss-of-function DNMs identified in schizophrenia patients

Gene	Rare variant frequency in SCZ	Rare variant frequency in control	SKAT <i>P</i> value
<i>GJC1</i>	0.0115	0.0091	$5.60 \times 10^{-3}$
<i>HIST1H2AD</i>	0.0029	0.0043	$6.28 \times 10^{-1}$

**Table 3.** Genes significantly enriched with higher DNM burden in schizophrenia patients than unaffected siblings

Gene symbol	DNM count in unaffected siblings	DNM count in schizophrenia patients	<i>P</i> -value	Bonferroni <i>P</i> -value
<i>DPYSL2</i>	0	6	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>NBPF1</i>	0	6	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>SDK1</i>	1	5	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>ZNF595</i>	1	5	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>ZNF718</i>	1	5	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>GCNT2</i>	0	5	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>SNX9</i>	0	5	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>KCNQ1</i>	1	4	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>AACS</i>	1	3	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$
<i>MSI2</i>	1	3	$1 \times 10^{-4}$	$3.4 \times 10^{-3}$

Figure 1




Figure 2






Figure 3




Figure 4




Figure 5

